Weltkarte Tuberkulose

Story

Tuberculosis: A treacherous sleeper

Tuberculosis - an epidemic from days gone by? Quite the opposite: the infectious disease still exists, even in Switzerland.

In 2020, 9.9 million people worldwide contracted tuberculosis and 1.5 million died from it. This makes tuberculosis the infectious disease with the second highest number of deaths worldwide after COVID-19. Most people with the disease live in the southern half of Africa and in Asia. But Switzerland still records around 500 cases a year.

Infection control through contact tracing

Most of the people infected with tuberculosis in Switzerland were infected in a country where tuberculosis is still widespread. The fact that the disease has been contained in Switzerland and has not spread further, even in new cases, is primarily due to the immediate isolation and prompt treatment of patients as well as rigorous contact tracing. The diagnosis is often not so easy to make at the beginning. “The symptoms are non-specific; fever, cough, general malaise, night sweats or weight loss are also common in many other diseases,” explains Silvan Vesenbeckh, senior physician at the Clinic for Pneumology.

“Sleeper” in the body

In addition, an infection with tuberculosis pathogens does not necessarily lead to illness. Although around 90 percent of those infected carry the bacterium, they have no symptoms and are not infectious to others. The defense cells form a wall around the pathogens and thus encapsulate them from the rest of the surrounding tissue. They can survive there for years without harming the infected person. However, this latent infection can become active, i.e. turn into a disease. For example, if the immune system is weakened and can no longer maintain the wall, such as in the case of an HIV infection or in old age. This means that people can suddenly fall ill even years after the actual infection.

A disease of the entire system

Tuberculosis is a droplet infection. “If the air breathed by a person with open pulmonary tuberculosis is inhaled over a long period of time, the person can become infected.” However, not every person with tuberculosis is infectious, explains Silvan Vesenbeckh. Because the bacteria usually enter the body via the respiratory tract, around 80 percent of reported cases of tuberculosis primarily affect the lungs. However, the pathogens can also infect other organs such as lymph nodes, pleura, bones, joints or the brain. The bacteria usually reach other organs via the lymph and bloodstream and form inflammatory foci there too. Without treatment, the disease can be fatal.

Therapy as a test of patience

The good news is that tuberculosis can be treated specifically and has a very good chance of being cured. However, the therapy is lengthy. Sick patients usually have to take a combination of different antibiotics for six months. This is not always easy for those affected. Even if the symptoms improve, the therapy must be continued to the end. Otherwise there is a risk of relapse or the development of resistance. Side effects often make therapy more difficult. “It is therefore very important to monitor the therapy closely,” says Silvan Vesenbeckh. Patients are accompanied by the medical team and the Lung League Zurich throughout their treatment.

New vaccine in the pipeline

Antibiotic resistance is one of the reasons why the development of a vaccine has increasingly come back into focus in recent decades. Development is time-consuming and cost-intensive. It can take years for the disease to break out. Conversely, this means that test subjects must be observed for years during drug development to determine whether the vaccination is effective. The live BCG vaccine has been around since the beginning of the 20th century. This works well to prevent serious illness in children and is therefore still used in areas with very high case numbers. “However, the protection does not last long, and in order to further contain tuberculosis through vaccination, adults should also be able to be vaccinated,” says Silvan Vesenbeckh. A vaccine from South Africa, which is still under development, now promises to do just that: It appears to reduce the risk of contracting the disease by around 50 percent – which would be considered very good protection.

Johannes Nemeth, you deal with latent tuberculosis infections. What is your research about?

Together with our partners in Seattle, USA, we found that mice could not be infected with tuberculosis a second time if they were already latently ill. This led the team to a bold hypothesis: we wondered whether a latent tuberculosis infection could also have a protective effect on other diseases.

Was the hypothesis confirmed?

In fact, we were able to prove that mice with latent tuberculosis disease do not become infected with other infectious diseases. What’s more, none of these mice developed cancer.

What goal are you pursuing based on the findings?

The long-term goal would be to be able to cure infectious diseases by administering an asymptomatic, non-pathogenic tuberculosis bacterium and thus training the immune system. HIV is the main focus here. At the end of 2020, the research team of the Swiss HIV cohort study was also able to demonstrate for the first time a reduced HIV viral load and fewer infections with other pathogens in people infected with HIV and simultaneously latent tuberculosis infection. We are still at the very beginning. But it is an approach that is worth pursuing.

Responsible professionals

Johannes Nemeth, PD Dr. med. univ.

Attending Physician, Department of Infectious Diseases and Hospital Epidemiology

Tel. +41 44 255 33 22
Specialties: Tuberculosis, HIV, bacterial infections